FY2026 EPS Estimates for REGENXBIO Cut by HC Wainwright

REGENXBIO Inc. (NASDAQ:RGNX) – Equities researchers at HC Wainwright lowered their FY2026 EPS estimates for REGENXBIO in a report issued on Friday, June 5th. HC Wainwright analyst Y. Chen now anticipates that the biotechnology company will post earnings per share of ($3.86) for the year, down from their prior estimate of ($3.38). HC Wainwright has a “Buy” rating and a $26.00 price target on the stock. The consensus estimate for REGENXBIO’s current full-year earnings is ($3.59) per share. HC Wainwright also issued estimates for REGENXBIO’s Q4 2026 earnings at ($1.22) EPS, Q1 2027 earnings at ($1.13) EPS, Q2 2027 earnings at ($1.03) EPS, Q3 2027 earnings at ($0.98) EPS and Q4 2027 earnings at ($0.93) EPS.

A number of other equities analysts have also weighed in on RGNX. The Goldman Sachs Group decreased their price target on shares of REGENXBIO from $14.00 to $12.00 and set a “neutral” rating on the stock in a report on Tuesday, February 10th. Morgan Stanley set a $16.00 price target on shares of REGENXBIO in a report on Friday, May 15th. Bank of America decreased their price target on shares of REGENXBIO from $25.00 to $14.00 and set a “buy” rating on the stock in a report on Friday, May 15th. Barclays decreased their price target on shares of REGENXBIO from $37.00 to $12.00 and set an “overweight” rating on the stock in a report on Friday, May 15th. Finally, Robert W. Baird set a $27.00 price target on shares of REGENXBIO in a report on Tuesday, February 10th. Nine equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $23.55.

REGENXBIO Stock Up 0.8%

Shares of RGNX opened at $6.13 on Tuesday. The firm has a market cap of $316.92 million, a PE ratio of -1.09 and a beta of 1.04. The company’s fifty day moving average is $8.12 and its two-hundred day moving average is $10.37. REGENXBIO has a fifty-two week low of $5.45 and a fifty-two week high of $16.19.

REGENXBIO (NASDAQ:RGNX) last announced its quarterly earnings results on Thursday, May 14th. The biotechnology company reported ($1.72) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.36) by ($0.36). The company had revenue of $6.39 million during the quarter, compared to analyst estimates of $25.84 million. REGENXBIO had a negative net margin of 330.23% and a negative return on equity of 232.50%.

Insider Buying and Selling at REGENXBIO

In related news, insider Steve Pakola sold 15,309 shares of REGENXBIO stock in a transaction on Monday, May 11th. The shares were sold at an average price of $11.02, for a total transaction of $168,705.18. Following the transaction, the insider owned 232,617 shares in the company, valued at approximately $2,563,439.34. The trade was a 6.17% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 14.22% of the company’s stock.

Hedge Funds Weigh In On REGENXBIO

Several hedge funds and other institutional investors have recently made changes to their positions in RGNX. AQR Capital Management LLC lifted its holdings in shares of REGENXBIO by 2,247.7% during the 1st quarter. AQR Capital Management LLC now owns 620,595 shares of the biotechnology company’s stock valued at $4,437,000 after acquiring an additional 594,161 shares in the last quarter. Jane Street Group LLC lifted its holdings in shares of REGENXBIO by 151.1% during the 1st quarter. Jane Street Group LLC now owns 414,067 shares of the biotechnology company’s stock valued at $2,961,000 after acquiring an additional 249,156 shares in the last quarter. Franklin Resources Inc. acquired a new position in shares of REGENXBIO during the 2nd quarter valued at $239,000. American Century Companies Inc. lifted its holdings in shares of REGENXBIO by 8.4% during the 2nd quarter. American Century Companies Inc. now owns 110,066 shares of the biotechnology company’s stock valued at $904,000 after acquiring an additional 8,487 shares in the last quarter. Finally, Prudential Financial Inc. acquired a new position in shares of REGENXBIO during the 2nd quarter valued at $87,000. Institutional investors and hedge funds own 88.08% of the company’s stock.

About REGENXBIO

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.